Clinical Trials
6 trialsNCT07415005 2026-05-05
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06378892 2024-04-23
ALK-PPL
Centro di Riferimento Oncologico - Aviano
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT06092086 2023-10-23
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Guangdong Association of Clinical Trials
Phase 2 Recruiting